{
  "buildId": "5lGULuFSFhUrfWgBpMJq_",
  "gssp": true,
  "isFallback": false,
  "page": "/calc/[...slug]",
  "props": {
    "__N_SSP": true,
    "pageProps": {
      "calc": {
        "before_use": "",
        "calc_type": "calculator",
        "chief_complaint_en": [
          "Lymphadenopathy"
        ],
        "cmeEndDate": "2025-07-25 00:00:00+00+48",
        "cmeLastReviewed": "2022-07-25 00:00:00+00+48",
        "cmeReleaseDate": "2020-10-08 00:00:00+00+00",
        "cmeVersion": "3906.1",
        "cme_status": "enabled",
        "content": {
          "about": {
            "evidence_based_medicine_en": "<p>The original derivation of the EUTOS Score came from a retrospective analysis of 1,223 European patients in the European Leukemia Network CML registry. All patients were treated with imatinib and divided into a learning cohort and a validation cohort. The prediction is based on a surrogate endpoint for survival of complete cytogenetic response at 18 months, but was found to also predict progression-free survival (PFS). &nbsp;</p>\n<p>An attempt to validate the score by a single institution found that the score was not predictive for survival (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22431574\" target=\"_blank\" rel=\"noopener\">Jabbour 2012</a>). There are six major studies showing the EUTOS score predicts outcomes (<a href=\"http://www.bloodjournal.org/content/120/21/3759\" target=\"_blank\" rel=\"noopener\">Hoffman 2012</a>, <a href=\"http://www.bloodjournal.org/content/120/21/3759\" target=\"_blank\" rel=\"noopener\">Hoffman 2013</a>, <a href=\"http://www.bloodjournal.org/content/120/21/3778?sso-checked=true\" target=\"_blank\" rel=\"noopener\">Tiribelli 2012</a>, <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22770911\" target=\"_blank\" rel=\"noopener\">Breccia 2012</a>, <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22770911\" target=\"_blank\" rel=\"noopener\">Uz 2013</a>, Yahng 2012) and three studies showing that it does not (<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22770911\" target=\"_blank\" rel=\"noopener\">Marin 2011</a>, <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/22431574\" target=\"_blank\" rel=\"noopener\">Jabbour 2012</a>, <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/24450386\" target=\"_blank\" rel=\"noopener\">Yamamoto 2014</a>).</p>\n<p>The EUTOS Score continues to evolve, with recent data from <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/26416462\" target=\"_blank\" rel=\"noopener\">Pfirrmann et al (2016)</a> showing that an EUTOS Long-Term Survival Score (ELTS) differentiated probability of death due to CML better than the original EUTOS Score.</p>",
            "formula_en": "<p>EUTOS Score = (7 &times; basophil) + (4 &times; spleen), where</p>\n<ul>\n<li>&ldquo;Basophil&rdquo; is basophils as a percentage of peripheral blood leukocytes, and</li>\n<li>&ldquo;Spleen&rdquo; is spleen size palpable below left costal margin, in cm.</li>\n</ul>\n<p>Probability of <strong><em>not </em></strong>achieving complete cytogenic response (CCyR) at 18 months = x / (1 + x), where x = exp(&minus;2.1007 + 0.0700 &times; basophils + 0.0402 &times; spleen size)</p>",
            "more_info_en": "<p>Interpretation:</p>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>EUTOS Score</strong></p>\n</td>\n<td>\n<p><strong>Risk category</strong></p>\n</td>\n<td>\n<p><strong>5 year progression-free survival*</strong></p>\n</td>\n<td>\n<p><strong>CCyR at 18 months*</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&le;87</p>\n</td>\n<td>\n<p>Low</p>\n</td>\n<td>\n<p>90%</p>\n</td>\n<td>\n<p>86%</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>&gt;87</p>\n</td>\n<td>\n<p>High</p>\n</td>\n<td>\n<p>82%</p>\n</td>\n<td>\n<p>66%</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p>*Response rates based on imatinib treatment only.<br>CCyR, complete cytogenetic response rate.</p>",
            "references_list": {
              "Clinical Practice Guidelines": [],
              "Manufacturer Website": [],
              "Original/Primary Reference": [
                {
                  "href": "http://www.ncbi.nlm.nih.gov/pubmed/21536864",
                  "text": "Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G, Guilhot F, Porkka K, Ossenkoppele G, Lindoerfer D, Simonsson B, Pfirrmann M, Hehlmann R. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011 Jul 21;118(3):686-92. doi: 10.1182/blood-2010-12-319038. Epub 2011 May 2."
                }
              ],
              "Other References": [
                {
                  "href": "https://www.ncbi.nlm.nih.gov/pubmed/21900102 ",
                  "text": "Marin D, Ibrahim AR, Goldman JM. European Treatment and Outcome Study (EUTOS) score for chronic myeloid leukemia still requires more confirmation. J Clin Oncol 2011;29:3944–5. "
                },
                {
                  "href": "https://www.ncbi.nlm.nih.gov/pubmed/22431574 ",
                  "text": "Jabbour E, Cortes J, Nazha A, O’Brien S, Quintas-Cardama A, Pierce S, Garcia-Manero G, Kantarjian H. EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience. Blood 2012;119:4524–6."
                },
                {
                  "href": "https://www.ncbi.nlm.nih.gov/pubmed/24450386 ",
                  "text": "Yamamoto E, Fujisawa S, Hagihara M, et al. European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients. Cancer Sci. 2014;105(1):105-9."
                },
                {
                  "href": "https://www.ncbi.nlm.nih.gov/pubmed/26416462 ",
                  "text": "Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia. 2016;30(1):48-56."
                }
              ],
              "Outcomes": [],
              "Validation": [
                {
                  "href": "http://www.bloodjournal.org/content/120/21/3759 ",
                  "text": "Hoffmann VS, Mayer J, Turkina AG, Hellmann A, Indrak K, Steegmann JL, Zaritskey A, Colita A, Lindoerfer D, Baccarani M. EUTOS score is also valid in CML patients not involved in clinical studies. Blood 2012;120:Abstract 3759."
                },
                {
                  "href": "https://www.ncbi.nlm.nih.gov/pubmed/23752173 ",
                  "text": "Hoffmann VS, Baccarani M, Lindoerfer D, et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 2013;27:2016–22."
                },
                {
                  "href": "http://www.bloodjournal.org/content/120/21/3778?sso-checked=true ",
                  "text": "Tiribelli M, Bonifacio M, Calistri E, et al. EUTOS score identifies cases with poor outcome in patients with early chronic phase chronic myeloid leukemia, though not predictive for optimal response to imatinib. Blood 2012;120:Abstract 3778.\t"
                },
                {
                  "href": "https://www.ncbi.nlm.nih.gov/pubmed/22770911",
                  "text": "Breccia M, Finsinger P, Loglisci G, Latagliata R, Mancini M, Salaroli A, Serrao A, Zacheo I, Alimena G. The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line. Leuk Res 2012;36:e209–10."
                },
                {
                  "href": "https://www.ncbi.nlm.nih.gov/pubmed/23540886 ",
                  "text": "Uz B, Buyukasik Y, Atay H, et al. EUTOS CML prognostic scoring system predicts ELN-based ‘event-free survival’ better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate. Hematology 2013;18:247–52."
                },
                {
                  "href": "",
                  "text": "Yahng SA, Jang EJ, Choi SY, et al. Comparison of Sokal, Hasford and EUTOS scores in terms of long-term treatment outcome according to the risks in each prognostic model: a single center data analyzed in 255 early chronic phase chronic myeloid leukemia patients treated with frontline imatinib mesylate. Blood 2012;120:Abstract 2794. "
                }
              ],
              "Validations": []
            }
          },
          "contributor": {
            "expert_name": [
              "Justin Taylor, MD"
            ]
          },
          "creator": [
            {
              "approved": null,
              "name": "Dr. Joerg Hasford",
              "qa_en": ""
            }
          ],
          "how_to_use": {
            "pearls_pitfalls_en": "<ul>\n<li>The EUTOS (European Treatment and Outcome Study) Score predicts survival and can also be used to predict the probability of complete cytogenetic response at 18 months.</li>\n<li>Has better predictive value than the <calculator id=\"2143\">Sokal Score</calculator>.</li>\n<li>Spleen size estimation is subjective; however, that subjectivity is also included in other CML prognostic scores.</li>\n<li>Developed in patients treated with imatinib, so outcomes may not apply with newer generation therapies.</li>\n</ul>",
            "use_case_en": "<p>Newly-diagnosed CML patients prior to discussions regarding prognosis and treatment options.</p>",
            "why_use_en": "<ul>\n<li>Estimates response to therapy to, and survival on, the reference TKI (tyrosine kinase inhibitor) imatinib.</li>\n<li>Only requires two values, which can be clinically detected prior to completing a bone marrow biopsy.</li>\n</ul>"
          },
          "next_steps": {
            "advice_en": "",
            "critical_actions_en": "<p>Can only be applied to a newly-diagnosed patient before starting therapy.</p>",
            "management_en": "<p>Though there is no broad consensus on management, a conservative strategy is to treat low-risk patients with imatinib and reserve newer-generation TKIs for high risk patients.</p>"
          },
          "related_resources": {
            "guidelines": [],
            "interests": [],
            "mdcalc_rating": [],
            "partner_contact": [],
            "sdm_tool": [],
            "teaching": [],
            "videos": []
          },
          "reviewer": []
        },
        "disease_en": [
          "Cancer",
          "Chemotherapy",
          "Hematologic Malignancy",
          "Leukemia/Lymphoma"
        ],
        "dosing": false,
        "equation_logic": "9bbd718423ed28f808901093f6336191",
        "equation_logic_text": "var calc_output = [];\n\nvar spl = parseFloat(spl);\nvar baso = parseFloat(baso);\nif (UOMSYSTEM == false) {\n  spl = spl*2.54;\n}\n\nvar msg, mini_msg;\nvar score = (7 * baso) + (4 * spl);\n\nvar x = Math.exp(-2.1007 + (0.0700 * baso) + (0.0402 * spl));\nnoCCgR = x / (1 + x);\nnoCCgR = parseInt(noCCgR * 100);\n\nvar msg = 'Estimated probability of <u>not</u> achieving complete cytogenic response at 18 months: ' + noCCgR + '%';\nvar msg1;\nvar msg2;\nvar msg3;\n\nswitch (true) {\n    case (score < 87):\n        mini_msg = 'Low risk group';\n        msg1 = 'Low';\n        msg2 = '86%';   //CCyR at 18 months\n        msg3 = '90';  // % 5-year PFS\n        break;\n    case (score >= 87):\n        mini_msg = 'High risk group';\n        msg1 = 'High';\n        msg2 = '66%';       //CCyR at 18 months\n        msg3 = '82';      // % 5-year PFS\n        break;\n    default:\n        console.log('error');\n}\n\ncalc_output.push({\n    name: 'mini',\n    value: score.toFixed(0),\n    value_text: 'points',\n    message: mini_msg\n});\ncalc_output.push({\n    name: 'EUTOS 1',\n    value: score.toFixed(0),\n    value_text: 'points',\n    message: 'EUTOS Score'\n});\ncalc_output.push({\n    name: 'EUTOS 2',\n    value: msg1,\n    value_text: 'risk',\n    message: msg3 + '% 5-year progression-free survival <br/>' + msg2 + ' complete cytogenic response (CCyR) at 18 months'\n});\ncalc_output.push({\n    name: 'EUTOS 3',\n    value: noCCgR,\n    value_text: '%',\n    message: 'Likelihood of NOT achieving CCyR'\n});",
        "favorite_id": 3906,
        "full_title_en": "EUTOS Score for Chronic Myelogenous Leukemia (CML)",
        "input_schema": [
          {
            "conditionality": "",
            "default": null,
            "label_en": "<p>Spleen size</p>",
            "name": "spl",
            "optional": false,
            "tips_en": "Maximum distance palpable below costal margin",
            "type": "textbox",
            "unit": "spleen"
          },
          {
            "conditionality": "",
            "default": null,
            "label_en": "<p>% basophils</p>",
            "name": "baso",
            "optional": false,
            "tips_en": "",
            "type": "textbox",
            "unit": "basophils"
          }
        ],
        "instructions_en": "<p>Use in newly-diagnosed patients before starting therapy.</p>",
        "logic_language": "javascript",
        "md5": "fc0574a0cf21458de8e218cdd6282ea6",
        "medium_description_en": "<p>Predicts outcomes after CML treatments, specifically adjusted for tyrosine kinase treatments.</p>",
        "purpose_en": [
          "Prognosis"
        ],
        "search_abbreviation_en": [
          "survival",
          "platelets",
          "basophil",
          "tyrosine kinase"
        ],
        "search_id": "c-3906",
        "seo": {
          "keywords_en": "Eutos, sokal, eutos score, european treatment and outcomes study, CML, leukemia, lymphoma, chronic myelogenous leukemia",
          "meta_description_en": "EUTOS Score predicts survival of CML based on clinical and lab information."
        },
        "short_description_en": "<p>CML outcomes.</p>",
        "short_title_en": "EUTOS Score",
        "slug": "eutos-score-chronic-myelogenous-leukemia-cml",
        "specialty_en": [
          "Hematology and Oncology"
        ],
        "system_en": [
          "Hematologic",
          "Oncologic"
        ]
      },
      "contributors": [
        {
          "contributors_page": false,
          "description": "<p>Justin Taylor, MD, is an assistant professor on the Leukemia Service at Memorial Sloan Kettering Cancer Center. He is board certified in internal medicine and medical oncology. He completed his internship and residency at Brigham and Women’s Hospital in Boston. His clinical and research focuses are on the basic biology and translational significance of somatic genetic mutations in hematologic malignancies.</p>",
          "firstName": "Justin",
          "hasDisclosure": [],
          "img": "justin-taylor.jpg",
          "lastName": "Taylor",
          "name": "Justin Taylor, MD",
          "signedCOI": true,
          "status": "Current",
          "target": "justin-taylor"
        }
      ],
      "creators": [
        {
          "about_en": "Joerg Hasford, MD, PhD, is a Professor of Medical Data Processing, Biometrics and Epidemiology at the University of Munich in Germany. He is the chairman of the Ethics Committee of the Bavarian Medical Association and the Working Group Medical Ethics Commissions in the Federal Republic of Germany. In 2000, he was awarded the Paul Martini Prize of the German Society of Medical computer science, Biometry and Epidemiology, Dr. Hasford has also published numerous articles and serves as an editor for Pharmacoepidemiology and Drug Safety publication.",
          "deceased": false,
          "description": "",
          "firstName": "",
          "img": "",
          "lastName": "",
          "name": "Dr. Joerg Hasford",
          "photo_en": "https://cdn-web-img.mdcalc.com/people/default.jpeg",
          "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=hasford+j%5Bau%5D",
          "signedCOI": false
        }
      ],
      "envs": {
        "CANONICAL_URL_ROOT": "https://www.mdcalc.com",
        "CONTENT_SERVER_TAG": "WEB_PROD",
        "RECAPTCHA_PUBLIC_KEY": "6Lcu1mMkAAAAAAwmSDO3I7JNaUo9YtZ3jnrzTP6a",
        "STRIPE_PUB_KEY": "pk_live_yYm2UzDzaudhFgqWcKbv9vH7"
      },
      "faqs": [
        {
          "cme_faq": {
            "answer": "<p>MDCalc&rsquo;s Continuing Medical Education (CME) service allows users to easily earn AMA PRA Category 1 CreditsTM through regular use of MDCalc. Simply put, on top of getting the best medical calculators in the world, your usage will help you achieve your annual CME requirements, including specialty CME, without any extra effort.</p>",
            "question": "What is MDCalc CME?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Yes, in support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and MDCalc Ltd. Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.</p>",
            "question": "Is MDCalc CME accredited?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Only United States attending physicians, nurse practitioners, nurses, and physician assistants are eligible for our CME service.</p>",
            "question": "Who can enroll and how?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>We have over 275 CME-eligible calculators across various specialties. You can read the clinical content supporting any CME calculators to start earning. Once you have viewed all the supporting content for a calculator, you will have officially earned the credit amount (0.5 credits) and will be able to redeem a certificate. For now, only calc content in CME-eligible calcs is eligible for CME credits, however, we&rsquo;ll be expanding our CME service to include more of our content in the future.</p>",
            "question": "What activities can I do to earn CME credits?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Simply use our search bar or visit our homepage to easily find CME-eligible calcs. You must be enrolled in our CME service to see which calcs are CME-eligible.</p>",
            "question": "Where can I find calcs with which I can earn credits?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Once you&rsquo;ve enrolled in our CME service, you will have a personal CME Dashboard where you can view all of your earned credits. You can navigate to the dashboard by clicking the CME button in the header at the top of any page.</p>",
            "question": "Where can I see which credits I’ve earned?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Go to your CME Dashboard and select the credits you&rsquo;d like to redeem, fill out a few dropdown answers about how you used the calc, and then proceed to checkout.</p>",
            "question": "How do I redeem CME credits?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>No. Earning credits as you use calcs is free, but either you (or your employer) will need to purchase an annual subscription to redeem your CME certificates.</p>",
            "question": "Are CME credits free?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Just like with earned credits, you can view your CME certificates on your CME Dashboard in the &ldquo;CME Certificates&rdquo; tab. Certificates include a list of all of the calcs for which CME was earned along with a tally of the specialty CME.</p>",
            "question": "Where can I see my CME certificates?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>One year from the date of purchase.</p>",
            "question": "How long do credits in an annual subscription last?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>General; Addiction and Controlled Substances; Cardiac Care; Domestic and Intimate Partner Violence; Geriatrics; HIV and Infectious Disease; Hospice, End-of-Life, Terminal Illness, and Palliative Care; Mental and Behavioral Health; Pain Management; Pediatrics; Stroke; and Trauma.</p>",
            "question": "What specialty CME credits are included in the plan?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Your gift card will be sent via email within 1-2 business days of making your purchase. You will be able to select from the following options - Visa, Amazon.com, Apple. Be sure to claim your gift card offer within 90 days of receiving the email.</p>\n<p>Your CME purchase may have implications for tax reporting purposes. The cost of your CME product may or may not be tax-deductible when used for professional purposes. Any reimbursed amount for incentives must be declared as personal income for tax purposes. Please consult your tax advisor. MDCalc does not provide tax advice.</p>",
            "question": "I ordered a CME package with a gift card. How does it work?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Per the new guidelines from ACCME, the receipt will separate the cost you paid into the cost of the gift card and the cost of the CME learning activity.</p>",
            "question": "What will show on my receipt for CME when it includes a gift card?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>You can get a refund (minus any promotional gift amount) within 30-days if the ease of earning and redeeming does not meet your expectations and if you have redeemed no more than 4 credits. Please email <a href=\"mailto:team@mdcalc.com\" target=\"_blank\" rel=\"noopener\">team@mdcalc.com</a> to request a refund.</p>",
            "question": "How do I get a refund if I'm not satisfied?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>You can upgrade your subscription throughout your billing cycle and pay the difference for a higher plan. You may request to downgrade your plan to a lower level to coincide with your next renewal. Please email <a href=\"mailto:team@mdcalc.com\" target=\"_blank\" rel=\"noopener\">team@mdcalc.com</a> to request changes.</p>",
            "question": "How do I later upgrade to a different plan if I need more credits?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Gift card plans are available for 1 year and do not auto-renew. Standard, non gift-card subscriptions are auto-renewed annually. You can disable the automatic renewal of your subscription at any time by emailing <a href=\"mailto:team@mdcalc.com\" target=\"_blank\" rel=\"noopener\">team@mdcalc.com</a>.</p>",
            "question": "Do CME plans auto-renew?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>If you&rsquo;re part of a team or practice that wants to sign up five or more physicians, please email us at <a href=\"mailto:team@mdcalc.com\" target=\"_blank\" rel=\"noopener\">team@mdcalc.com</a> for more information.</p>",
            "question": "How do I get information on a discounted bulk subscription program for my institution, team, or practice?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>On July 28, 2022, ACCME updated the guidelines regarding the use of high-value incentives. These guidelines allow for the use of gift card rewards in a regulated manner. Visit the ACCME website to read their guidelines.</p>",
            "question": "Did the ACCME decide to regulate gift cards?",
            "type": "Purchasing"
          }
        }
      ],
      "headConfig": {
        "canonicalUrl": "/calc/3906/eutos-score-chronic-myelogenous-leukemia-cml",
        "description": "EUTOS Score predicts survival of CML based on clinical and lab information.",
        "keywords": "Eutos, sokal, eutos score, european treatment and outcomes study, CML, leukemia, lymphoma, chronic myelogenous leukemia",
        "title": "EUTOS Score for Chronic Myelogenous Leukemia (CML)"
      },
      "isCMECalc": true,
      "measurements": [
        {
          "conversion": "1",
          "error_max": "100.01",
          "error_max_si": 100.01,
          "error_max_us": "100.01",
          "error_min": "-0.01",
          "error_min_si": -0.01,
          "error_min_us": "-0.01",
          "name": "% Basophils",
          "normal_max_si": "2",
          "normal_max_us": "2",
          "normal_min_si": "0",
          "normal_min_us": "0",
          "unit": "basophils",
          "units_si": "%",
          "units_us": "%",
          "warn_max": "100",
          "warn_max_si": 100,
          "warn_max_us": "100",
          "warn_min": "0",
          "warn_min_si": 0,
          "warn_min_us": "0"
        },
        {
          "conversion": "0.39370079",
          "error_max": "20",
          "error_max_si": 7.8740158,
          "error_max_us": "20",
          "error_min": "0",
          "error_min_si": 0,
          "error_min_us": "0",
          "name": "Max distance of spleen from costal margin",
          "normal_max_si": "5",
          "normal_max_us": "12.7",
          "normal_min_si": "0",
          "normal_min_us": "0",
          "unit": "spleen",
          "units_si": "in",
          "units_us": "cm",
          "warn_max": "10",
          "warn_max_si": 3.9370079,
          "warn_max_us": "10",
          "warn_min": "0",
          "warn_min_si": 0,
          "warn_min_us": "0"
        }
      ],
      "relCalcs": [
        {
          "calcId": 2143,
          "short_title_en": "Sokal Score",
          "slug": "sokal-index-chronic-myelogenous-leukemia-cml"
        },
        {
          "calcId": 2320,
          "short_title_en": "FLIPI for Follicular Lymphoma",
          "slug": "follicular-lymphoma-international-prognostic-index-flipi"
        },
        {
          "calcId": 10040,
          "short_title_en": "Duval/CIBMTR Score",
          "slug": "duval-cibmtr-score-acute-myelogenous-leukemia-aml-survival"
        }
      ],
      "societies": {
        "American Association for the Study of Liver Diseases": {
          "abbreviation": "AASLD",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/cdn-web-img.mdcalc.com/logo/other_society.png",
          "web_link": "https://www.aasld.org/"
        },
        "American College Of Emergency Physicians": {
          "abbreviation": "ACEP",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/apps.mdcalc.com/images/american-college-of-emergency-physicians-squarelogo.png",
          "web_link": "https://www.acep.org/"
        },
        "American College of Gastroenterology": {
          "abbreviation": "ACG",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/cdn-web-img.mdcalc.com/logo/acg_logo.png",
          "web_link": "https://gi.org/"
        },
        "American College of Rheumatology": {
          "abbreviation": "ACR",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/cdn-web-img.mdcalc.com/logo/other_society.png",
          "web_link": "https://www.rheumatology.org/"
        },
        "American Gastroenterological Association": {
          "abbreviation": "AGA",
          "description": "plain-text",
          "img": "https://apps.mdcalc.com/images/societies/aga.jpeg",
          "web_link": "https://gastro.org"
        },
        "American Heart Association": {
          "abbreviation": "AHA",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/apps.mdcalc.com/images/societies/+AHA+(American+Heart+Association).png",
          "target": "aha",
          "web_link": "http://www.heart.org/HEARTORG/"
        },
        "American Urological Association": {
          "abbreviation": "AUA",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/cdn-web-img.mdcalc.com/logo/other_society.png",
          "web_link": "https://www.auanet.org/"
        },
        "EB Medicine": {
          "abbreviation": "EB Medicine",
          "description": "EB Medicine is the premier provider of evidence-based clinical content and CME resources for emergency medicine practitioners.",
          "img": "https://cdn-web-img.mdcalc.com/other/eb_medicine-icon-only.jpg",
          "target": "eb-medicine",
          "web_link": "http://www.ebmedicine.net/"
        },
        "MDCalc CME": {
          "abbreviation": "MDCalc CME",
          "img": "https://cdn-web-img.mdcalc.com/Stroke-CME-content.jpg",
          "web_link": "https://www.mdcalc.com/stroke-cme?utm_source=NIHSS_calc&utm_medium=NIHSS_calc&utm_campaign=NIHSS_calc"
        },
        "OTHER": {
          "abbreviation": "OTHER"
        },
        "Postgraduate Institute for Medicine": {
          "abbreviation": "PIM",
          "description": "plain-text",
          "img": "https://cdn-web-img.mdcalc.com/PIM-circle-COLOR.jpeg",
          "target": "pim",
          "web_link": "https://www.pimed.com/"
        },
        "VACO Podcast": {
          "description": "Listen to the VACO co-creators break down how to use VACO\\, what it does\\, and what it doesn’t.",
          "img": "https://cdn-web-img.mdcalc.com/content/podcast 2.png",
          "web_link": "https://www.stimuluspodcast.com/post/32-the-covid-mortality-score-vaco"
        }
      },
      "validSections": [
        "whenToUseViewed",
        "pearlsPitfallsViewed",
        "whyUseViewed",
        "nextStepsViewed",
        "evidenceViewed"
      ]
    }
  },
  "query": {
    "slug": [
      "3906",
      "eutos-score-chronic-myelogenous-leukemia-cml"
    ]
  },
  "scriptLoader": []
}